NASDAQ:DOVA - Dova Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$10.76 +0.13 (+1.22 %)
(As of 05/19/2019 03:08 AM ET)
Previous Close$10.76
Today's Range$10.61 - $10.90
52-Week Range$5.62 - $35.33
Volume95,740 shs
Average Volume135,022 shs
Market Capitalization$303.75 million
P/E RatioN/A
Dividend YieldN/A
Beta2.06
Dova Pharmaceuticals, Inc., a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead product candidate is DOPTELET that is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease scheduled to undergo a procedure. It also develops DOPTELET for the treatment of chronic immune thrombocytopenia and chemotherapy-induced thrombocytopenia. Dova Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Durham, North Carolina.

Receive DOVA News and Ratings via Email

Sign-up to receive the latest news and ratings for DOVA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:DOVA
CUSIPN/A
Phone919-748-5975

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$10.35 million
Book Value$2.24 per share

Profitability

Net Income$-72,280,000.00
Net Margins-521.67%

Miscellaneous

Employees115
Market Cap$303.75 million
Next Earnings Date8/8/2019 (Estimated)
OptionableOptionable

Dova Pharmaceuticals (NASDAQ:DOVA) Frequently Asked Questions

What is Dova Pharmaceuticals' stock symbol?

Dova Pharmaceuticals trades on the NASDAQ under the ticker symbol "DOVA."

How were Dova Pharmaceuticals' earnings last quarter?

Dova Pharmaceuticals Inc (NASDAQ:DOVA) issued its quarterly earnings results on Tuesday, May, 7th. The company reported ($0.58) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.68) by $0.10. The company earned $4 million during the quarter, compared to analyst estimates of $3.46 million. Dova Pharmaceuticals had a negative net margin of 521.67% and a negative return on equity of 87.20%. View Dova Pharmaceuticals' Earnings History.

When is Dova Pharmaceuticals' next earnings date?

Dova Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, August 8th 2019. View Earnings Estimates for Dova Pharmaceuticals.

What price target have analysts set for DOVA?

6 brokers have issued twelve-month price targets for Dova Pharmaceuticals' shares. Their predictions range from $18.00 to $44.00. On average, they anticipate Dova Pharmaceuticals' share price to reach $30.8333 in the next year. This suggests a possible upside of 186.6% from the stock's current price. View Analyst Price Targets for Dova Pharmaceuticals.

What is the consensus analysts' recommendation for Dova Pharmaceuticals?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dova Pharmaceuticals in the last year. There are currently 1 sell rating, 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Dova Pharmaceuticals.

What are Wall Street analysts saying about Dova Pharmaceuticals stock?

Here are some recent quotes from research analysts about Dova Pharmaceuticals stock:
  • 1. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We maintain our Buy rating and $18 price target. Our valuation is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug’s potential commercial profile. Our valuation is currently based on the opportunity for avatrombopag in the CLD, cITP, and CIT indications broken down as follows: (1) CLD contributes 61.1% of our valuation ($206 million peak sales projection in the U.S.); (2) cITP contributes 31.8% of our valuation ($174 million peak sales projection in the U.S." (4/26/2019)
  • 2. According to Zacks Investment Research, "Dova Pharmaceuticals, Inc. is a pharmaceutical company. It focuses on acquiring, developing and commercializing drug candidates for thrombocytopenia diseases. The company's drug candidate includes avatrombopag, an orally administered thrombopoietin receptor agonist which are in clinical stage. Dova Pharmaceuticals, Inc. is based in Durham, North Carolina. " (10/30/2018)
  • 3. Jefferies Financial Group Inc analysts commented, "About 6 weeks into Doptelet launch, DOVA has been pleased with reimbursement levels (not seeing pushback from payers); plans to provide some key metrics, including % Rx getting reimbursed by payers on 2Q18 call." (7/15/2018)

Has Dova Pharmaceuticals been receiving favorable news coverage?

Media stories about DOVA stock have been trending negative recently, according to InfoTrie. The research group ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Dova Pharmaceuticals earned a daily sentiment score of -2.1 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the near future.

Who are some of Dova Pharmaceuticals' key competitors?

What other stocks do shareholders of Dova Pharmaceuticals own?

Who are Dova Pharmaceuticals' key executives?

Dova Pharmaceuticals' management team includes the folowing people:
  • Dr. David S. Zaccardelli, Pres & CEO (Age 54)
  • Mr. Mark W. Hahn, CFO & Sec. (Age 56)
  • Mr. Kevin Laliberte, Sr. VP of Product Devel. (Age 41)
  • Mr. Jason Levine, VP of Marketing
  • Mr. Ilija Zlatar, Head of U.S. Sales

When did Dova Pharmaceuticals IPO?

(DOVA) raised $66 million in an initial public offering (IPO) on Thursday, June 29th 2017. The company issued 4,100,000 shares at $15.00-$17.00 per share. J.P. Morgan, Jefferies and Leerink Partners served as the underwriters for the IPO.

Who are Dova Pharmaceuticals' major shareholders?

Dova Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include FMR LLC (4.77%), BlackRock Inc. (4.10%), Sanders Morris Harris LLC (1.00%), Northern Trust Corp (0.58%), Morgan Stanley (0.57%) and Wells Fargo & Company MN (0.32%). Company insiders that own Dova Pharmaceuticals stock include Alex Sapir, David Zaccardelli, Jason Hoitt, Kevin Laliberte, Lee F Md Phd Allen, Life Sciences Maste Perceptive, Paul B Manning and Steven M Goldman. View Institutional Ownership Trends for Dova Pharmaceuticals.

Which institutional investors are selling Dova Pharmaceuticals stock?

DOVA stock was sold by a variety of institutional investors in the last quarter, including Fosun International Ltd, Wells Fargo & Company MN, Northern Trust Corp, Raymond James & Associates, Charles Schwab Investment Management Inc. and Citigroup Inc.. View Insider Buying and Selling for Dova Pharmaceuticals.

Which institutional investors are buying Dova Pharmaceuticals stock?

DOVA stock was acquired by a variety of institutional investors in the last quarter, including Sanders Morris Harris LLC, Morgan Stanley, Renaissance Technologies LLC, Spark Investment Management LLC, FMR LLC, Birchview Capital LP, BlackRock Inc. and State of Wisconsin Investment Board. Company insiders that have bought Dova Pharmaceuticals stock in the last two years include Alex Sapir, David Zaccardelli, Kevin Laliberte, Lee F Md Phd Allen, Life Sciences Maste Perceptive, Paul B Manning and Steven M Goldman. View Insider Buying and Selling for Dova Pharmaceuticals.

How do I buy shares of Dova Pharmaceuticals?

Shares of DOVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Dova Pharmaceuticals' stock price today?

One share of DOVA stock can currently be purchased for approximately $10.76.

How big of a company is Dova Pharmaceuticals?

Dova Pharmaceuticals has a market capitalization of $303.75 million and generates $10.35 million in revenue each year. The company earns $-72,280,000.00 in net income (profit) each year or ($2.60) on an earnings per share basis. Dova Pharmaceuticals employs 115 workers across the globe.

What is Dova Pharmaceuticals' official website?

The official website for Dova Pharmaceuticals is http://www.dova.com.

How can I contact Dova Pharmaceuticals?

Dova Pharmaceuticals' mailing address is 240 Leigh Farm Road Suite 245, Durham NC, 27707. The company can be reached via phone at 919-748-5975 or via email at [email protected]


MarketBeat Community Rating for Dova Pharmaceuticals (NASDAQ DOVA)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  166 (Vote Outperform)
Underperform Votes:  158 (Vote Underperform)
Total Votes:  324
MarketBeat's community ratings are surveys of what our community members think about Dova Pharmaceuticals and other stocks. Vote "Outperform" if you believe DOVA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DOVA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 5/19/2019 by MarketBeat.com Staff

Featured Article: What is the Rule of 72?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel